GM-DEP- MEEC .90--Operations Update6/17@5:35PM
Midwest Energy Emissions Corp. Provides Operations Update 06/17 05:37 PM
WORTHINGTON, Ohio, June 17, 2013 /PRNewswire/ -- Midwest Energy Emissions Corp. (OTCQB: MEEC) today announces an update on its current operations and offers a market discussion by its President and CEO.
As background, in April of 2012, the U.S. EPA's Mercury and Air Toxics Standards (MATS) rule was finalized, requiring U.S. coal and oil-fired units over 25 megawatts in size to reduce mercury emissions by approximately 90% (the exact amount depending on the mercury content in the fuel burned), starting in April 2015. The EPA believes that this law affects 1,100 coal and 300 oil-fired units and estimates the annual cost of compliance with the new standards to be approximately $9 billion. Currently, several states have established their own limits on mercury emissions, providing for a near-term market opportunity for MEEC; while the major market for mercury removal resulting from MATS's deadline for compliance will be realized in less than two years. All power plants affected by the MATS rule will be required to be fully compliant with the MATS standards by April 2015 (with a one year extension available in certain circumstances). This new mercury emissions capture services market will create a large and on-going, annual revenue stream for the very best suppliers of such services.
Alan Kelley, President and Chief Executive Officer said, "We announced earlier this year that we had signed agreements with two major US power producers in the Southwest to perform demonstrations of our mercury removal technology on several of their units. We are pleased to report that all the demonstrations went very well and achieved the results that we expected, which, in each case, included getting mercury emissions below the MATS limit. We anticipate discussions and negotiations with these utilities for long-term supply contracts for their mercury emissions control. In addition, we are in discussions with other utilities for demonstrations on their units this summer and early fall. It is a very busy time for our company, but our operating results continue to demonstrate success in getting unit emissions under the MATS limits with the least effect on balance of plant systems for any supplier that we know of. "
Mr. Kelley continued, "For an average size coal unit of about 500 megawatts, the cost of achieving a 90% reduction in mercury emissions utilizing our technology will typically be between $2 million and $5 million per year. Therefore, for purposes of calculating potential income for the company, we estimate that each average-sized unit will generate approximately $3.5 million in revenue for MEEC. EPA estimates the number of coal units affected by the regulation to be about 1100, so there is a large market for services such as MEEC's that will emerge in 2015."
"As utilities finalize their plans for MATS compliance by the April 2015 deadline, we anticipate more demonstrations over the next nine months or so. We also anticipate a very active competitive market in the 2016-2020 time-frame, as utilities look at the results achieved by other utilities and switch to technologies offering better overall value, such as ours," concluded Mr. Kelley.
About Midwest Energy Emissions Corp. (MEEC:$0.90,00$0.00,000.00%) (ME2C)
We deliver cost effective mercury capture technologies to power plant and other large industrial coal-burning units in the United States and Canada. Our proprietary technology allows customers to meet even the new, highly restrictive standards the U.S. EPA has set for mercury emissions, in an effective and economical manner with the least disruption to the current equipment and on-going operations. For more information, see our website at www.midwestemissions.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the federal securities laws. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. The words, "believe," "project," "expect," "anticipate," "estimate," "will" and other similar statements of expectation identify forward-looking statements. Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. Matters that may cause actual results to differ materially from those in the forward-looking statements include, among other factors, the gain or loss of a major customer, change in environmental regulations, disruption in supply of materials, a significant change in general economic conditions in any of the regions where our customer utilities might experience significant changes in electric demand, a significant disruption in the supply of coal to our customer units, the loss of key management personnel, failure to obtain adequate working capital to execute the business plan and any major litigation regarding the Company. In addition, this release contains time-sensitive information that reflects management's best analysis only as of the date of this release. The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance related to forward-looking statements contained in this release can be found in the Company's periodic filings with the Securities and Exchange Commission.
CONTACT: Keith R. McGee
Director of Investor Relations
kmcgee@midwestemissions.com
(614) 505-6115
SOURCE Midwest Energy Emissions Corp. (MEEC:$0.90,00$0.00,000.00%)
Get more news on:SYMBOLS: MEECNEWS TYPE: SECTORS: Energy, Oil, Gas and Consumable Fuels, Industrials, Commercial Services and Supplies, Utilities
GM-DEP-MEEC .90--Operations Update6/17@5:35PM Midwest
Top 10 Most Recent News Articles
BASIS Bellevue Expands with New K-4 Campus
A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...
Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer
Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...
Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move
Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...
Continue Reading
Amgen Q3 2026 Results: What Investors Should Know
Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...
Continue Reading
Royce Global Trust: Insights on RGT's Performance
Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...
Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy
Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...
Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence
New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...
Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030
Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...
Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?
Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...
Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions
When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...
Continue ReadingTop 5 Most Recently Viewed Articles
Innovative AI Assistant by ClickBid Revolutionizes Fundraising
ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...
Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars
Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...
Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference
Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...
Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge
Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...
Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone
MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...
Continue Reading